Feline Acromegaly (Hypersomatotropism)

Feline acromegaly, also termed hypersomatotropism (HST), is an endocrine disorder arising from chronic, excessive secretion of growth hormone (GH) in adult cats, virtually always caused by a functional pituitary adenoma [2]. The sustained GH excess drives hepatic production of insulin-like growth factor 1 (IGF-1), which mediates most of the anabolic and metabolic consequences of the disease [2]. Acromegaly is now recognized as one of the most clinically significant causes of secondary diabetes mellitus (DM) in cats, estimated to underlie approximately 15–25% of all feline diabetic cases [1]. The condition is progressive and, if unrecognized, leads to poorly regulated diabetes, organomegaly, and multi-system complications that substantially reduce quality and duration of life [4].

Primary cause Feline acromegaly is caused almost exclusively by a GH-secreting pituitary adenoma, typically a benign macroadenoma of the pars distalis [2]. Unlike human acromegaly—where ectopic GH or GH-releasing hormone (GHRH) excess occasionally occurs—no such ectopic source has been substantively documented in cats [7].

Genetic predisposition Research into the aryl-hydrocarbon receptor interacting protein (AIP) gene has revealed sequence variants in feline acromegalic patients, paralleling the AIP mutations found in up to 20% of familial isolated pituitary adenomas in humans [5]. Acromegalic sibling pairs have been documented in cats, suggesting a possible heritable component, though most cases appear sporadic [5].

GH/IGF-1 axis dysregulation The pituitary adenoma secretes GH in an autonomous, non-pulsatile, and largely unregulated manner. GH binds hepatic receptors to stimulate production of IGF-1, the principal mediator of tissue growth effects [2]. IGF-1 promotes cellular proliferation and anabolic activity in soft tissue, bone, cartilage, and visceral organs, producing the characteristic changes of acromegaly [7].

Insulin resistance and secondary diabetes GH directly antagonizes insulin signaling at the post-receptor level, inducing profound peripheral insulin resistance [1][3]. The pancreatic beta cells initially compensate with increased insulin secretion, but progressive GH excess eventually overwhelms beta-cell capacity, precipitating overt DM [3]. The resulting diabetes is often severe and labile, with markedly elevated insulin requirements [1][4]. Glucolipotoxicity from chronic hyperglycemia further damages residual beta-cell function, perpetuating the diabetic state [3].

Demographic pattern Affected cats are predominantly middle-aged to older, neutered males, with a mean age at diagnosis typically between 10 and 13 years [4][7]. There is no well-established breed predisposition, though certain studies have noted possible over-representation of domestic shorthair cats simply reflecting population demographics [2].

Clinical suspicion Acromegaly should be strongly suspected in any middle-aged to older cat presenting with poorly controlled or insulin-resistant DM, especially when accompanied by weight gain, facial coarsening, or organomegaly [4][8]. A high index of suspicion is essential because clinical signs may be subtle early in the disease course.

Serum IGF-1 measurement Measurement of serum IGF-1 concentration is the most widely used first-line screening test; elevated IGF-1 (typically >1000 ng/mL, though laboratory reference intervals vary) has high sensitivity for acromegaly in the appropriate clinical context [2][4][8]. IGF-1 must be interpreted cautiously alongside other findings, as false elevations can occasionally occur with exogenous progestagen exposure or other growth-promoting states [4].

Advanced imaging Magnetic resonance imaging (MRI) of the brain is the gold-standard modality for identifying and characterizing the pituitary adenoma; computed tomography (CT) is a practical alternative when MRI is unavailable [2][7]. Adenomas may range from microadenomas to large macroadenomas causing local mass effect or extension beyond the sella turcica [4][7].

Laboratory findings

• ·Persistent fasting hyperglycemia: often severe (>400 mg/dL / >22 mmol/L) and difficult to normalize [1]
• ·Elevated fructosamine: reflects prolonged poor glycemic control [6][8]
• ·Elevated serum IGF-1: the biochemical cornerstone of diagnosis [2][4]
• ·Elevated ALT and ALP: hepatic enzyme elevations are common, reflecting hepatomegaly and hepatic lipidosis secondary to uncontrolled diabetes [2]
• ·Elevated BUN and CREA: azotemia may reflect concurrent CKD, a recognized complication of acromegaly-related systemic hypertension and glomerulopathy [4]
• ·Hypercholesterolemia and hypertriglyceridemia: metabolic consequences of GH excess and poor diabetic control [2]
• ·Urine glucose (glycosuria) ± ketonuria: on urinalysis, consistent with uncontrolled DM [2]
• ·HCT: usually normal; significant anemia may suggest concurrent disease
• ·PLT: typically normal
• ·Echocardiography is recommended to screen for hypertrophic cardiomyopathy, which is a significant complication [7]
• ·Blood pressure measurement: systemic hypertension is reported and warrants routine assessment [4]

Exclusion of differentials Other causes of insulin resistance—hyperadrenocorticism, progestagen therapy, and hyperthyroidism—must be excluded through appropriate testing (low-dose dexamethasone suppression test, progestagen history, serum total T4) before or concurrent with acromegaly workup [4].

Pituitary radiation therapy (primary treatment) External beam radiation therapy (conventionally fractionated or stereotactic radiosurgery such as CyberKnife) directed at the pituitary adenoma is considered the most effective currently available treatment modality for feline acromegaly [2][7]. Radiation can reduce GH and IGF-1 concentrations, improve insulin sensitivity, and facilitate diabetic remission in a subset of patients; clinical improvement may take weeks to months to become apparent [2][7].

Transsphenoidal hypophysectomy Surgical removal of the pituitary gland via a transsphenoidal approach has been performed at specialist centers and can result in rapid normalization of GH/IGF-1 and diabetic remission [7]. This procedure requires significant surgical expertise and is associated with perioperative risks including diabetes insipidus, electrolyte disturbances, and infection, limiting its widespread use [7].

Medical management — cabergoline Cabergoline, a dopamine agonist, has been evaluated as a medical option for cats with HST and concurrent DM. In a prospective cohort study, cabergoline administered at 10 µg/kg every 48 hours orally for 6 months was associated with reductions in serum IGF-1 and fructosamine concentrations and reduced insulin dose requirements in some cats [6]. While not uniformly effective for normalizing GH secretion, cabergoline represents a potentially accessible, non-invasive option, particularly where radiation or surgery is unavailable [6].

Medical management — somatostatin analogues and GH receptor antagonists Octreotide (a somatostatin analogue) and pegvisomant (a GH receptor antagonist) have been used in humans with acromegaly; veterinary application is limited by cost, availability, and variable efficacy in cats, and these are not considered standard-of-care in most practices [7].

Insulin therapy for concurrent diabetes All acromegalic cats with DM require insulin therapy, often at substantially higher doses than typical diabetic cats [1][4]. Intermediate- or long-acting insulin formulations (e.g., protamine zinc insulin [PZI], glargine) are commonly employed [8]. Continuous or flash glucose monitoring can assist in managing the highly variable glucose profiles seen in these patients [8]. Dose adjustments should be gradual and carefully monitored given the risk of hypoglycemia if GH levels decline following definitive treatment [4].

Supportive and ancillary care

• ·Dietary management: a low-carbohydrate, high-protein diet supports glycemic control in diabetic cats [8]
• ·Cardiac management: cats with acromegaly-associated cardiomyopathy may require specific cardiac medications (e.g., atenolol, clopidogrel) guided by echocardiographic findings [7]
• ·Antihypertensive therapy (e.g., amlodipine) if systemic hypertension is documented [4]
• ·Monitoring and management of CKD if present [4]
• ·Regular re-evaluation of IGF-1, fructosamine, insulin dose, blood pressure, and echocardiography is recommended [7][8]

Prognosis for feline acromegaly is guarded to poor without definitive treatment, as the underlying pituitary adenoma continues to grow and GH excess progressively worsens [2][4]. Cats with uncontrolled or poorly managed disease face ongoing risks from refractory DM, cardiac failure (hypertrophic cardiomyopathy is a leading cause of death), advancing neurological signs from tumor expansion, and CKD [7].

Survival with radiation therapy: median survival times reported following radiation therapy range broadly, with some studies reporting survival times of approximately 1.5–2.5 years post-radiation, and a subset of cats achieving long-term diabetic remission [2][7]. Improvements in stereotactic radiosurgery techniques have been associated with more favorable outcomes in recent case series [7].

Survival with hypophysectomy: surgical hypophysectomy has been associated with relatively rapid endocrine remission and survival times comparable to or exceeding those achieved with radiation in specialist settings, though perioperative mortality is a recognized risk [7].

Medical management alone: cats managed only with insulin and cabergoline—without radiation or surgery—generally have shorter survival times and poorer glycemic control, though cabergoline can achieve partial clinical benefit in some cases [6]. Cabergoline use resulted in improved insulin resistance indices and reduced IGF-1 in a proportion of treated cats, but complete remission was not consistently achieved [6].

Overall: Without any treatment directed at the pituitary tumor, many cats are euthanized within months to 1–2 years of diagnosis due to unmanageable diabetes, cardiac complications, or neurological deterioration [4][7]. With the best available therapies (radiation or surgery at specialist centers), meaningful extensions of good-quality life are achievable, though long-term cure is uncommon. Data on precise population-wide mortality rates are limited in the current veterinary literature, but the condition is ultimately progressive and fatal if the underlying pituitary adenoma is not addressed [2][4][7].

There is currently no known vaccine or specific prophylactic intervention for feline acromegaly, as the disease arises from spontaneous pituitary adenoma formation [2]. Given the possible role of AIP gene variants in predisposition, avoidance of breeding from affected cats and their close relatives may be prudent, though definitive genetic screening programs are not yet established in veterinary practice [5].

Progestagen avoidance: In cats, exogenous progestagens (e.g., megestrol acetate, medroxyprogesterone acetate) stimulate mammary GH secretion and can independently cause GH excess and secondary DM; avoiding or minimizing progestagen use removes a preventable risk factor for GH-related disorders [4].

Early detection in at-risk populations: While not strictly preventive, routine screening of middle-aged to older neutered male diabetic cats—particularly those showing poor insulin response—with serum IGF-1 measurement can enable earlier diagnosis and intervention before severe end-organ damage occurs [1][4][8]. Early identification and treatment may slow disease progression and improve quality of life even if complete prevention is not possible.

Weight management: Given that obesity independently predisposes to insulin resistance and DM, maintaining a healthy body condition score may reduce the metabolic burden on the pancreatic beta cells, though this does not prevent the pituitary tumor itself [3].